Compare Bank of New York Mellon Corp (BNY) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of New York Mellon Corp vs Humana Inc — how do they compare? Bank of New York Mellon Corp trades at $163 (market cap $108.78B), while Humana Inc trades at $374.25 (market cap $44.77B). The key difference: Bank of New York Mellon Corp is far larger — about 2.4× Humana Inc's market cap, and Bank of New York Mellon Corp pays the higher dividend (1.38%). Which is the better fit depends on your goals.
| BNY | HUM | |
|---|---|---|
Market Cap | $108.78B | $44.77B |
Sector | Financials | Health |
52-Week High | $162.35 | $409.42 |
52-Week Low | $101.00 | $163.67 |
Dividend Yield | 1.38% | 0.95% |
Enterprise Value | — | $52.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNY stock trades at $162.98, up 2.22% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported record Q2 2026 results with EPS of $2.46, surpassing estimates, and announced a strategic collaboration to advance digital asset infrastructure. Revenue growth is steady, rising to $19.76B in 2025, with a net income margin of 29.96%.
Outlook remains positive with a consensus price target of $170.36, though risks include high investing cash outflows and competitive pressures. The stock's current price is near the consensus target, suggesting limited upside without further catalysts. Institutional sentiment is mixed, with 45% buy ratings and 55% hold.
Humana (HUM) trades at $388.96, up 0.9% with a neutral technical signal. The stock shows strong revenue growth reaching $129.7B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent earnings beat expectations for three consecutive quarters, while analyst consensus targets $409.93. The company maintains solid cash flow generation and recently announced key leadership appointments to strengthen its Medicaid business.
Humana presents a mixed outlook with robust revenue expansion offset by margin pressures. Investment opportunity lies in Medicare Advantage growth and cost reduction initiatives, while risks include competitive pressures and regulatory changes in healthcare. Wall Street maintains cautious optimism with 39% buy ratings amid margin recovery challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
